What are my equipment options for taking Pulmozyme?

You have options for taking Pulmozyme. The first option uses a jet nebulizer and a compressor. The second option uses a nebulizer system. Talk to your doctor about which option is right for you.

Here’s why you need a nebulizer and compressor for Pulmozyme:

  • A nebulizer changes the Pulmozyme liquid medicine into a fine mist you inhale by breathing through a mouthpiece 
  • A compressor gives the nebulizer power and makes the nebulizer work 

What are my options for taking Pulmozyme?

Several nebulizer and compressor combinations are FDA-approved for use with Pulmozyme:

Jet Nebulizers + Compressors
Hudson T Up-draft II® with Pulmo-Aide®
Marquest Acorn II® with Pulmo-Aide®
PARI LC® Plus PARI PRONEB® 
*PARI BABY™ PARI PRONEB® 
Durable Sidestream® with MOBILAIRE™
Durable Sidestream® with Porta-Neb®

The Pari eRapid is a Fast, Quiet and portable Nebulizer system option:

Nebulizer systems for Pulmozyme® (dornase alfa) administration

The eRapid system:

  • Uses mesh technology which operates differently than jet nebulizers
  • Is FDA 510 cleared for use as a general nebulizer system
  • Delivers treatment in a system that is small and portable.

Talk to your doctor about which nebulizer system is best for you and your treatment plan.

Distributors may be able to help with benefits coverage. For more information on eRapid, call PARI at (866) 335-6943, or visit PARI.com.

*Patients who are unable to inhale or exhale orally through the entire nebulization period may use the PARI BABY nebulizer.

Consisting of the eRapid® Nebulizer Handset with eBase Controller.
The average nebulization time for the eRapid Nebulizer System is approximately 2-3 minutes compared to the LC® Plus Jet Nebulizer, which is 6-10 minutes.

Take Pulmozyme on the go

Nebulizer system for Pulmozyme® (dornase alfa) administration

The Pulmozyme cooler bag was developed for patients to transport Pulmozyme when traveling or on the go. 

Patients can request one via 1-888-PLMZYME (1-888-756-9963).

 

What to do next?

Talk to your doctor about which equipment might be right for you

Financial assistance

Looking for financial support?

Check out the financial assistance programs available to help patients, with or without insurance

Indication & Usage

Pulmozyme (dornase alfa) is indicated for daily administration along with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.

In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.

Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients.

Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion, and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.

Pediatric Use

The safety and effectiveness of Pulmozyme have been established in patients 5 years of age and older. While clinical trial data are limited in patients younger than 5 years of age, the use of Pulmozyme should be considered for pediatric CF patients who may experience potential benefit in lung function or who may be at risk of respiratory tract infection.

The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to <10 years (older group). The PARI BABY™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. Overall, the kind of side effects observed in children was similar to those seen in larger trials in older patients.

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full Pulmozyme Prescribing Information for additional Important Safety Information. If you have questions, please discuss them with your CF Care Team.